Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance

Amylx Pharmaceuticals IncTrade
State Street SPDR S&P Homebuilders ETFTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs State Street SPDR S&P Homebuilders ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while State Street SPDR S&P Homebuilders ETF trades at $108.31. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals.

AMLXXHB
Market Cap
$2.64B
Sector
HealthBroad Market / Factor
52-Week High
$24.19$121.36
52-Week Low
$7.82$94.86
Enterprise Value
$2.39B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.

The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.

State Street SPDR S&P Homebuilders ETF

XHB trades at $108.71 with a modest 0.43% daily gain, showing bullish technical momentum with strong moving average signals. The ETF benefits from positive housing market developments including new home sales growth and supportive legislation, though mixed economic data creates uncertainty. Technical indicators show overbought conditions with RSI at 71.56, suggesting potential near-term consolidation.

The housing sector outlook remains cautiously optimistic with legislative support and improving builder sentiment offsetting high mortgage rate concerns. Key risks include interest rate sensitivity and inventory constraints, while institutional positioning adjustments reflect strategic portfolio rebalancing rather than sector pessimism.

Returns comparison

Trailing returns across standard periods

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About State Street SPDR S&P Homebuilders ETF

XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.

Read more on XHB